Sweden
· Delayed Price · Currency is SEK IRLAB Therapeutics AB Statistics
Total Valuation
STO:IRLAB.A has a market cap or net worth of SEK 372.42 million. The enterprise value is 350.27 million.
| Market Cap | 372.42M |
| Enterprise Value | 350.27M |
Important Dates
The last earnings date was Monday, April 21, 2025.
| Earnings Date | Apr 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:IRLAB.A has 51.87 million shares outstanding.
| Current Share Class | 51.79M |
| Shares Outstanding | 51.87M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 21.60% |
| Owned by Institutions (%) | 25.15% |
| Float | 33.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.63 |
| PB Ratio | 80.40 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.49 |
| EV / Sales | 3.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -16.49 |
Financial Position
The company has a current ratio of 0.68, with a Debt / Equity ratio of 14.35.
| Current Ratio | 0.68 |
| Quick Ratio | 0.68 |
| Debt / Equity | 14.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.13 |
| Interest Coverage | -4.74 |
Financial Efficiency
Return on equity (ROE) is -191.89% and return on invested capital (ROIC) is -47.11%.
| Return on Equity (ROE) | -191.89% |
| Return on Assets (ROA) | -27.88% |
| Return on Invested Capital (ROIC) | -47.11% |
| Return on Capital Employed (ROCE) | -904.83% |
| Revenue Per Employee | 3.31M |
| Profits Per Employee | -2.52M |
| Employee Count | 31 |
| Asset Turnover | 0.69 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.14% in the last 52 weeks. The beta is 0.44, so STO:IRLAB.A's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -44.14% |
| 50-Day Moving Average | 7.24 |
| 200-Day Moving Average | 11.91 |
| Relative Strength Index (RSI) | 54.68 |
| Average Volume (20 Days) | 19,292 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:IRLAB.A had revenue of SEK 102.69 million and -78.08 million in losses. Loss per share was -1.51.
| Revenue | 102.69M |
| Gross Profit | -29.52M |
| Operating Income | -66.12M |
| Pretax Income | -78.08M |
| Net Income | -78.08M |
| EBITDA | -61.53M |
| EBIT | -66.12M |
| Loss Per Share | -1.51 |
Balance Sheet
The company has 88.61 million in cash and 66.46 million in debt, giving a net cash position of 22.14 million or 0.43 per share.
| Cash & Cash Equivalents | 88.61M |
| Total Debt | 66.46M |
| Net Cash | 22.14M |
| Net Cash Per Share | 0.43 |
| Equity (Book Value) | 4.63M |
| Book Value Per Share | 0.09 |
| Working Capital | -48.23M |
Cash Flow
In the last 12 months, operating cash flow was -21.05 million and capital expenditures -199,000, giving a free cash flow of -21.25 million.
| Operating Cash Flow | -21.05M |
| Capital Expenditures | -199,000 |
| Free Cash Flow | -21.25M |
| FCF Per Share | -0.41 |
Margins
Gross margin is -28.75%, with operating and profit margins of -64.39% and -76.04%.
| Gross Margin | -28.75% |
| Operating Margin | -64.39% |
| Pretax Margin | -76.04% |
| Profit Margin | -76.04% |
| EBITDA Margin | -59.93% |
| EBIT Margin | -64.39% |
| FCF Margin | n/a |
Dividends & Yields
STO:IRLAB.A does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -20.97% |
| FCF Yield | -5.70% |
Stock Splits
The last stock split was on May 28, 2019. It was a forward split with a ratio of 5.
| Last Split Date | May 28, 2019 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |